Kidney Rejection Articles & Analysis
3 news found
VEL-101/FR104 is a novel investigational maintenance immunosuppressive agent being developed for prevention of acute rejection in kidney transplant recipients. “Dosing our first participant in this study is a monumental step for Veloxis and our growth as a global pharmaceutical development company” said Mark Hensley, chief executive officer of ...
(Nasdaq: SGMO), a genomic medicine company, today announced dosing of the first patient in the Phase 1/2 STEADFAST clinical study evaluating TX200, a wholly-owned autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation from a living ...
Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has published preliminary data on its kidney transplant rejection test, ExoTRU (Exosome Transplant Rejection Urine), a non-invasive multigene urine-based exosomal mRNA assay. ...